Germ Cell Cancer
8
1
3
3
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
12.5%
1 terminated out of 8 trials
75.0%
-11.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (8)
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
Acute Changes in Endothelial Function in Germ Cell Tumor Patients Treated With Cisplatin and Untreated Germ Cell Tumor Controls
Genomic Structural Variation in Cancer Susceptibility
YASU Research Registry: For Young Adults With Cancer
SerUm and Plasma MicroRNAs in Malignant Ovarian gERm Cell Tumours
Toxicity Attributed to Genetic Polymorphisms in Testicular Germ Cell Tumor Survivors
Brentuximab Vedotin (SGN-35) as Salvage Treatment for CD30-positive Germ Cell Tumors
Everolimus for Patients With Relapsed/Refractory Germ Cell Cancer